CliffBio
small molecule

ATOVAQUONE

ATOVAQUONE

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameATOVAQUONE
Active ingredientATOVAQUONE
Strength750MG/5ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2018
Marketing statusDISCN

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.